Financials Caplin Point Laboratories Limited NSE India S.E.

Equities

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - NSE India S.E. 05:13:54 28/06/2024 pm IST 5-day change 1st Jan Change
1,473 INR -0.38% Intraday chart for Caplin Point Laboratories Limited +3.44% +8.59%

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 30,430 21,358 30,571 51,529 45,291 1,12,218 - -
Enterprise Value (EV) 1 30,430 21,358 30,571 51,529 45,291 1,00,038 1,12,218 1,12,218
P/E ratio - 10 x 12.7 x 17.3 x 12.1 x 22 x 21.4 x 19.9 x
Yield - 0.89% 0.74% 0.29% 0.34% 0.21% 0.22% 0.25%
Capitalization / Revenue 4.69 x 2.47 x 2.88 x 4.06 x 3.09 x 5.91 x 5.71 x 5.07 x
EV / Revenue 4.69 x 2.47 x 2.88 x 4.06 x 3.09 x 5.91 x 5.71 x 5.07 x
EV / EBITDA 12.2 x 7.09 x 9.3 x 13.1 x 10.3 x 18.1 x 17.7 x 15.9 x
EV / FCF - -66.6 x 15.7 x 21 x 58.1 x 52.7 x 34.2 x 28.2 x
FCF Yield - -1.5% 6.39% 4.77% 1.72% 1.9% 2.92% 3.55%
Price to Book 4.83 x 2.27 x 2.58 x 3.47 x 2.41 x 4.87 x 3.63 x 3.24 x
Nbr of stocks (in thousands) 75,630 75,643 75,643 75,789 75,903 76,010 - -
Reference price 2 402.4 282.4 404.2 679.9 596.7 1,476 1,476 1,476
Announcement Date 22/05/19 18/06/20 06/05/21 12/05/22 27/05/23 16/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,487 8,632 10,613 12,694 14,667 16,941 19,670 22,140
EBITDA 1 2,504 3,014 3,286 3,947 4,411 5,514 6,328 7,072
EBIT - - 3,152 3,478 4,520 - 6,028 7,060
Operating Margin - - 29.7% 27.4% 30.82% - 30.65% 31.89%
Earnings before Tax (EBT) 1 - 2,695 3,136 3,858 4,514 5,644 6,422 6,846
Net income 1 - 2,150 2,423 2,998 3,763 4,571 5,226 5,618
Net margin - 24.91% 22.83% 23.62% 25.65% 26.98% 26.57% 25.38%
EPS 2 - 28.20 31.71 39.26 49.18 59.90 68.95 74.13
Free Cash Flow 1 - -320.6 1,953 2,456 779 2,128 3,277 3,982
FCF margin - -3.71% 18.4% 19.35% 5.31% 12.57% 16.66% 17.99%
FCF Conversion (EBITDA) - - 59.43% 62.22% 17.66% 36.28% 51.79% 56.31%
FCF Conversion (Net income) - - 80.6% 81.9% 20.7% 46.55% 62.71% 70.88%
Dividend per Share 2 - 2.500 3.000 2.000 2.000 3.150 3.300 3.650
Announcement Date 22/05/19 18/06/20 06/05/21 12/05/22 27/05/23 16/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2022 Q1 2022 Q2 2022 Q3 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 2,744 3,004 3,035 3,262 3,463 3,590 3,721 3,893 3,953 4,111 4,381 4,462
EBITDA 1 897.5 926.1 1,012 - 1,022 1,056 1,094 1,239 1,266 1,234 1,395 2,986
EBIT - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - -
Net income 1 644.6 708.5 749.8 - 849.9 916.7 974.8 1,021 1,034 970 1,179 1,232
Net margin 23.49% 23.58% 24.7% - 24.54% 25.53% 26.2% 26.23% 26.16% 23.6% 26.91% 27.62%
EPS - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 04/02/21 05/08/21 02/11/21 03/02/22 05/08/22 12/11/22 11/02/23 27/05/23 07/08/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -321 1,953 2,456 779 2,128 3,277 3,983
ROE (net income / shareholders' equity) 35.4% 27.2% 22.7% 22.5% 22.4% 20.9% 19.7% 17.5%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 83.30 124.0 157.0 196.0 248.0 303.0 406.0 456.0
Cash Flow per Share - - - - - - - -
Capex 1 - 767 733 912 1,938 1,304 1,000 1,000
Capex / Sales - 8.89% 6.91% 7.18% 13.21% 7.71% 5.08% 4.52%
Announcement Date 22/05/19 18/06/20 06/05/21 12/05/22 27/05/23 16/05/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,476 INR
Average target price
1,569 INR
Spread / Average Target
+6.25%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CAPLIPOINT Stock
  4. CAPLIPOINT Stock
  5. Financials Caplin Point Laboratories Limited